# Innovent Biologics (Suzhou) Co. Ltd. trials: 199 (2026)

ClinicalTrials.gov lists 199 trials with Innovent Biologics (Suzhou) Co. Ltd. as lead sponsor, 44 of them recruiting or not yet recruiting.

## The full list

Clinical trials led by Innovent Biologics (Suzhou) Co. Ltd.: 199 rows for $9.95, every trial on ClinicalTrials.gov. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. The new rows each week by email, about 3 rows a month: $19 a month. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/company/innovent-biologics-suzhou-co-ltd

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 199
- Recruiting or not yet: 44
- Read on: November 19, 2026

## Trials

The 25 newest of 199, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| November 4, 2026 | NCT07917468 | Sintilimab Combined With LCCRT Followed by Capeox Chemotherapy in pMMR/MSS/MSI-L Locally Advanced Rectal Cancer | Innovent Biologics (Suzhou) Co. Ltd. | Phase 3 | Not yet recruiting | Locally Advanced Rectal Cancer | 500 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07917468) |
| October 29, 2026 | NCT07902804 | A Study of IBI3043 Treatment in Participants With Locally Advanced, Unresectable or Metastatic Solid Tumors | Innovent Biologics (Suzhou) Co. Ltd. | Phase 1 | Not yet recruiting | Solid Tumors | 604 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07902804) |
| October 21, 2026 | NCT07886476 | IBI3034 Study in Healthy Adults and Patients With Primary IgA Nephropathy | Innovent Biologics (Suzhou) Co. Ltd. | Phase 1 | Not yet recruiting | IgA Nephropathy (IgAN) | 100 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07886476) |
| September 25, 2026 | NCT07842497 | A Study of Efficacy and Safety of IBI3011 in Subjects With Acute Gouty Arthritis | Innovent Biologics (Suzhou) Co. Ltd. | Phase 2 | Recruiting | Acute Gouty Arthritis | 132 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07842497) |
| September 24, 2026 | NCT07838220 | A Study of IBI3016 in Japanese Participants | Innovent Biologics (Suzhou) Co. Ltd. | Phase 1 | Recruiting | Hypertension | 30 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07838220) |
| September 23, 2026 | NCT07836660 | A Study of IBI355 in Participants With Moderate-to-Severe Sjögren's Disease | Innovent Biologics (Suzhou) Co. Ltd. | Phase 2 | Not yet recruiting | Sjögren's Disease | 198 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07836660) |
| September 9, 2026 | NCT07809945 | A Study of IBI3046 in Participants With Overweight or Obesity | Innovent Biologics (Suzhou) Co. Ltd. | Phase 1 | Recruiting | Obesity and Overweight | 128 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07809945) |
| August 28, 2026 | NCT07793019 | IBI3042 Study in Healthy Participants and Overweight or Obese Participants | Innovent Biologics (Suzhou) Co. Ltd. | Phase 1 | Recruiting | Overweight, Healthy Participants, Obesity | 104 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07793019) |
| August 14, 2026 | NCT07765160 | Clinical Trials of IBI3040 in Healthy Participants and Overweight or Obese Participants | Innovent Biologics (Suzhou) Co. Ltd. | Phase 1 | Not yet recruiting | Healthy Participants, Overweight or Obese Participants | 96 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07765160) |
| August 14, 2026 | NCT07764861 | A Open-Label Phase in Participants With Multiple Myeloma | Innovent Biologics (Suzhou) Co. Ltd. | Phase 2 | Not yet recruiting | Multiple Myeloma | 120 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07764861) |
| August 10, 2026 | NCT07754786 | A Study to Evaluate the Equivalence of IBI3027 and Dupilumab Injection in Participants With Moderate to Severe Atopic Dermatitis | Innovent Biologics (Suzhou) Co. Ltd. | Phase 3 | Recruiting | Atopic Dermatitis | 520 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07754786) |
| July 23, 2026 | NCT07722494 | IBI363 Combined With Bevacizumab for Advanced Colorectal Cancer | Innovent Biologics (Suzhou) Co. Ltd. | Phase 3 | Recruiting | Colorectal Cancer | 550 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07722494) |
| June 3, 2026 | NCT07623798 | A Study in Participants With Relapsed or Refractory Multiple Myeloma for IBI3003 | Innovent Biologics (Suzhou) Co. Ltd. | Phase 3 | Recruiting | Relapsed or Refractory Multiple Myeloma | 255 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07623798) |
| June 3, 2026 | NCT07622368 | A Study of IBI3031 in Participants With Thyroid Eye Disease | Innovent Biologics (Suzhou) Co. Ltd. | Phase 1 | Recruiting | Thyroid Eye Disease | 66 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07622368) |
| May 28, 2026 | NCT07612137 | Study of IBI3005 Combination Therapy in Participants With Unresectable, Locally Advanced or Metastatic Solid Tumors | Innovent Biologics (Suzhou) Co. Ltd. | Phase 1/2 | Not yet recruiting | Solid Tumor | 282 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07612137) |
| May 15, 2026 | NCT07591519 | Clinical Trials of IBI3035 in Healthy Subjects | Innovent Biologics (Suzhou) Co. Ltd. | Phase 1 | Recruiting | Healthy Person | 144 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07591519) |
| April 30, 2026 | NCT07559019 | Safety and Preliminary Activity of BI115 in Advanced SCLC | Innovent Biologics (Suzhou) Co. Ltd. | Phase 1 | Recruiting | Small Cell Lung Cancer (SCLC) | 150 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07559019) |
| April 29, 2026 | NCT07556796 | Study of IBI3016 in People With Mild or Moderate Hypertension Patients | Innovent Biologics (Suzhou) Co. Ltd. | Phase 1 | Active not recruiting | Hypertension | 30 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07556796) |
| April 28, 2026 | NCT07554222 | Study to Evaluate the Safety, Tolerability and How IBI3013 is Taken up and Processed by the Body in Healthy Volunteers After Single-dose... | Innovent Biologics (Suzhou) Co. Ltd. | Phase 1 | Recruiting | Healthy, Active Non-segmental Vitiligo, Severe Alopecia Areata | 160 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07554222) |
| April 24, 2026 | NCT07549984 | A Study of IBI3033 in Moderate-to-Severe Atopic Dermatitis | Innovent Biologics (Suzhou) Co. Ltd. | Phase 1 | Not yet recruiting | Atopic Dermatitis | 16 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07549984) |
| March 31, 2026 | NCT07502534 | A Clinical Study Comparing the Bioequivalence of IBI3027 and DUPIXENT®(Dupilumab) in Healthy Chinese Volunteers | Innovent Biologics (Suzhou) Co. Ltd. | Phase 1 | Active not recruiting | Healthy Volunteers | 180 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07502534) |
| March 19, 2026 | NCT07483567 | IBI343 in Combination With Sintilimab and SOX Regimen for Perioperative Treatment of Resectable, Locally Advanced Gastric or... | Innovent Biologics (Suzhou) Co. Ltd. | Phase 2 | Recruiting | CLDN18.2 Positive, Primary Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma | 90 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07483567) |
| March 19, 2026 | NCT07483554 | IBI343 in Combination Therapy for Advanced Malignant Solid Tumors | Innovent Biologics (Suzhou) Co. Ltd. | Phase 2 | Recruiting | CLDN18.2 Positive, Gastric/Gastroesophageal Junction Adenocarcinoma, Pancreatic Ductal Adenocarcinoma | 389 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07483554) |
| March 16, 2026 | NCT07473960 | IBI306 Monotherapy in Non-Familial Hypercholesterolemia and Mixed Hyperlipidemia | Innovent Biologics (Suzhou) Co. Ltd. | Phase 3 | Completed | Non-Familial Hypercholesterolemia and Mixed Hyperlipidemia | 198 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07473960) |
| March 13, 2026 | NCT07469800 | Efficacy and Safety of IBI362 in Hypertensive Patients With Overweight/Obesity | Innovent Biologics (Suzhou) Co. Ltd. | Phase 3 | Recruiting | Overweight, Obesity, Hypertensive | 336 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07469800) |

## By phase

| Phase | Trials |
| --- | --- |
| Phase 1 | 95 |
| Phase 1/2 | 22 |
| Phase 2 | 35 |
| Phase 2/3 | 3 |
| Phase 3 | 40 |
| Phase 4 | 1 |
| Observational | 3 |

## By status

| Status | Trials |
| --- | --- |
| Completed | 102 |
| Recruiting | 32 |
| Terminated | 17 |
| Active not recruiting | 17 |
| Unknown | 12 |
| Not yet recruiting | 12 |
| Suspended | 4 |
| Withdrawn | 3 |

## Conditions

| Condition group | Trials |
| --- | --- |
| Obesity | 10 |
| Carcinoma, Non-Small-Cell Lung | 7 |
| Overweight | 7 |
| Graves Ophthalmopathy | 6 |
| Diabetes Mellitus, Type 2 | 5 |
| Dermatitis, Atopic | 4 |
| Psoriasis | 4 |
| Hypercholesterolemia | 4 |
| Melanoma | 4 |
| Neoplasms | 4 |
| Colorectal Neoplasms | 4 |
| Carcinoma, Hepatocellular | 3 |
| Multiple Myeloma | 3 |
| Recurrence | 3 |
| Small Cell Lung Carcinoma | 3 |
| Lymphoma | 3 |
| Hypertension | 3 |
| Asthma | 2 |
| Esophageal Squamous Cell Carcinoma | 2 |
| Lymphoma, Large B-Cell, Diffuse | 2 |
| Lymphoma, Follicular | 2 |
| COVID-19 | 2 |
| Hematologic Neoplasms | 1 |
| Colitis, Ulcerative | 1 |
| Sjogren's Syndrome | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Deck builders in the United States](https://specstream.ai/data/businesses/deck-builders/united-states)
- [Temp agencies in the United States](https://specstream.ai/data/businesses/temp-agencies/united-states)
- [Irish restaurants in the United States](https://specstream.ai/data/businesses/irish-restaurants/united-states)
- [Breakfast and brunch restaurants in the United States](https://specstream.ai/data/businesses/breakfast-and-brunch-restaurants/united-states)
- [Rail freight companies in the United States](https://specstream.ai/data/businesses/rail-freight-companies/united-states)
- [Forklift dealers in the United States](https://specstream.ai/data/businesses/forklift-dealers/united-states)
